Frontiers in Endocrinology

Effects of SGLT2 inhibitors on body composition and potential sarcopenia-related outcomes in type 2 diabetes mellitus: a network meta-analysis

By Xiaona Li, Yanrui Zhang, Luxun Wang, Yuanyuan Zhao

Meta-analysis of randomised trialsInterventions

Preregistered CRD420261379719

The paper

Xiaona Li, Yanrui Zhang, Luxun Wang, Yuanyuan Zhao

Yellow River Central Hospital

Frontiers in Endocrinology, 29 Jul 2026

doi.org/10.3389/fendo.2026.1877008 PubMed 42591093

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression